vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and SITIME Corp (SITM). Click either name above to swap in a different company.
SITIME Corp is the larger business by last-quarter revenue ($113.3M vs $75.5M, roughly 1.5× PUMA BIOTECHNOLOGY, INC.). On growth, SITIME Corp posted the faster year-over-year revenue change (66.3% vs 27.7%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $13.0M). Over the past eight quarters, SITIME Corp's revenue compounded faster (85.2% CAGR vs 31.3%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
PBYI vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $113.3M |
| Net Profit | — | $9.2M |
| Gross Margin | 69.3% | 56.4% |
| Operating Margin | 22.7% | 1.6% |
| Net Margin | — | 8.1% |
| Revenue YoY | 27.7% | 66.3% |
| Net Profit YoY | — | 148.7% |
| EPS (diluted) | $0.26 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | $113.3M | ||
| Q3 25 | $54.5M | $83.6M | ||
| Q2 25 | $52.4M | $69.5M | ||
| Q1 25 | $46.0M | $60.3M | ||
| Q4 24 | $59.1M | $68.1M | ||
| Q3 24 | $80.5M | $57.7M | ||
| Q2 24 | $47.1M | $43.9M | ||
| Q1 24 | $43.8M | $33.0M |
| Q4 25 | — | $9.2M | ||
| Q3 25 | $8.8M | $-8.0M | ||
| Q2 25 | $5.9M | $-20.2M | ||
| Q1 25 | $3.0M | $-23.9M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $20.3M | $-19.3M | ||
| Q2 24 | $-4.5M | $-26.8M | ||
| Q1 24 | $-4.8M | $-28.7M |
| Q4 25 | 69.3% | 56.4% | ||
| Q3 25 | 77.7% | 53.5% | ||
| Q2 25 | 76.5% | 51.9% | ||
| Q1 25 | 77.1% | 50.3% | ||
| Q4 24 | 76.4% | 52.6% | ||
| Q3 24 | 63.9% | 51.1% | ||
| Q2 24 | 77.4% | 49.1% | ||
| Q1 24 | 75.5% | 53.5% |
| Q4 25 | 22.7% | 1.6% | ||
| Q3 25 | 17.6% | -19.2% | ||
| Q2 25 | 12.7% | -35.4% | ||
| Q1 25 | 8.7% | -46.6% | ||
| Q4 24 | 22.6% | -33.8% | ||
| Q3 24 | 27.4% | -43.1% | ||
| Q2 24 | -4.6% | -73.7% | ||
| Q1 24 | -5.3% | -106.1% |
| Q4 25 | — | 8.1% | ||
| Q3 25 | 16.2% | -9.6% | ||
| Q2 25 | 11.2% | -29.0% | ||
| Q1 25 | 6.5% | -39.6% | ||
| Q4 24 | — | -27.6% | ||
| Q3 24 | 25.2% | -33.5% | ||
| Q2 24 | -9.6% | -61.0% | ||
| Q1 24 | -11.0% | -86.9% |
| Q4 25 | $0.26 | $0.44 | ||
| Q3 25 | $0.17 | $-0.31 | ||
| Q2 25 | $0.12 | $-0.84 | ||
| Q1 25 | $0.06 | $-1.01 | ||
| Q4 24 | $0.40 | $-0.80 | ||
| Q3 24 | $0.41 | $-0.83 | ||
| Q2 24 | $-0.09 | $-1.16 | ||
| Q1 24 | $-0.10 | $-1.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | — |
| Total DebtLower is stronger | $22.7M | — |
| Stockholders' EquityBook value | $130.3M | $1.2B |
| Total Assets | $216.3M | $1.3B |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | — | ||
| Q2 25 | $96.0M | — | ||
| Q1 25 | $93.2M | — | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | — | ||
| Q2 24 | $96.8M | — | ||
| Q1 24 | $107.2M | — |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
| Q4 25 | $130.3M | $1.2B | ||
| Q3 25 | $115.3M | $1.1B | ||
| Q2 25 | $104.7M | $1.1B | ||
| Q1 25 | $97.1M | $692.5M | ||
| Q4 24 | $92.1M | $699.7M | ||
| Q3 24 | $71.1M | $696.2M | ||
| Q2 24 | $48.5M | $692.5M | ||
| Q1 24 | $51.0M | $696.2M |
| Q4 25 | $216.3M | $1.3B | ||
| Q3 25 | $202.9M | $1.3B | ||
| Q2 25 | $194.9M | $1.3B | ||
| Q1 25 | $196.2M | $872.1M | ||
| Q4 24 | $213.3M | $885.0M | ||
| Q3 24 | $220.7M | $877.9M | ||
| Q2 24 | $205.0M | $878.6M | ||
| Q1 24 | $214.1M | $942.6M |
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $25.4M |
| Free Cash FlowOCF − Capex | $14.4M | $13.0M |
| FCF MarginFCF / Revenue | 19.1% | 11.5% |
| Capex IntensityCapex / Revenue | 0.0% | 10.9% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | $35.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $25.4M | ||
| Q3 25 | $9.7M | $31.4M | ||
| Q2 25 | $14.1M | $15.3M | ||
| Q1 25 | $3.6M | $15.0M | ||
| Q4 24 | $15.6M | $13.5M | ||
| Q3 24 | $11.0M | $8.2M | ||
| Q2 24 | $1.0M | $-181.0K | ||
| Q1 24 | $11.2M | $1.7M |
| Q4 25 | $14.4M | $13.0M | ||
| Q3 25 | $9.7M | $26.3M | ||
| Q2 25 | $14.1M | $-2.9M | ||
| Q1 25 | $3.6M | $-1.3M | ||
| Q4 24 | $15.6M | $-2.4M | ||
| Q3 24 | $11.0M | $-6.7M | ||
| Q2 24 | $1.0M | $-2.7M | ||
| Q1 24 | — | $-1.2M |
| Q4 25 | 19.1% | 11.5% | ||
| Q3 25 | 17.7% | 31.5% | ||
| Q2 25 | 26.8% | -4.2% | ||
| Q1 25 | 7.7% | -2.1% | ||
| Q4 24 | 26.4% | -3.5% | ||
| Q3 24 | 13.7% | -11.6% | ||
| Q2 24 | 2.1% | -6.3% | ||
| Q1 24 | — | -3.6% |
| Q4 25 | 0.0% | 10.9% | ||
| Q3 25 | 0.0% | 6.1% | ||
| Q2 25 | 0.0% | 26.2% | ||
| Q1 25 | 0.1% | 27.0% | ||
| Q4 24 | 0.0% | 23.3% | ||
| Q3 24 | 0.0% | 25.7% | ||
| Q2 24 | 0.0% | 5.8% | ||
| Q1 24 | 0.0% | 8.8% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
